Company intelligence / Profile preview

Kryptos Biotechnologies

Hayward, California, United Stateskryptosbio.com ↗

Ownership: Private
Employees: ~7
Development stage: Preclinical

Overview

Kryptos Biotechnologies has developed a proprietary point-of-care qPCR molecular diagnostics system ("KUICK") that delivers sample-to-answer results in under 25 minutes with lab-level accuracy. The company is advancing clinical studies of its respiratory combo test panels to support FDA approval by 2025. Its single-cell multinomics platform enables rapid precision medicine applications by generating comprehensive molecular profiles from individual cells within one day.

Therapeutic areas: Infectious Diseases
Modalities: DevicePCR-based diagnostics (Point-of-care molecular diagnostic system)Single-cell analysis platform
Industry: Molecular Diagnostics

Partnerships

Osang Healthcare (strategic partnership for manufacturing and distribution)

Beyond the preview

Go deeper on Kryptos Biotechnologies.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Kryptos Biotechnologies.

Explore the full profile